After calling UnitedHealthcare's refusal to cover proton therapy for cancer "immoral and barbaric," a federal judge -- and cancer survivor -- recused himself from a case involving one of those coverage denials. (CNN)
A new cancer research initiative in England focuses on turning cancer into a chronic disease rather than trying to kill it. (Daily Mail)
And the winner is ... A computer simulation of 12 different cervical cancer screening strategies identified one that offers "a reasonable balance of benefits, harms, and costs." (University of California San Francisco, JAMA Internal Medicine)
With summer fast approaching, "five things to know about melanoma." (CMAJ)
A California jury decided on an unprecedented $2 billion award for a couple who said that their cancer resulted from chronic exposure to the weedkiller Roundup ... just weeks after the Environmental Protection Agency reaffirmed that glyphosate (a key ingredient in Roundup) is not carcinogenic. (CNN)
Tissue "scaffolds" produced by 3D printers might offer a new source of tissue for nipple and areola reconstruction after mastectomy. (Tissue Engineering, University of Queensland)
The Community Oncology Alliance launched a national campaign to stop pharmacy benefit manager "abuses" and draw attention to "real life patient horror stories."
Genentech announced FDA approval of the chemotherapy-free combination of venetoclax (Venclexta) and obinutuzumab (Gazyva) as first-line therapy for chronic lymphocytic leukemia.
And based on the JAVELIN Renal 101 trial, the FDA approved the first-line combination of avelumab (Bavencio) plus axitinib (Inlyta) for advanced renal cell carcinoma.
Medicare contractors drafted a proposal to limit coverage of tumor treating field therapy for glioblastoma to patients with newly diagnosed disease. (MedTech Dive)
Older cancer survivors receive opioid medication for years after diagnosis and treatment, and the rate has increased in recent years. (Journal of the American Geriatrics Society, UTMB Health)
Agios announced that a phase III clinical trial of ivosidenib (Tibsovo) met the primary endpoint of improved progression-free survival in patients with previously treated IDH1-mutant cholangiocarcinoma.
The CDC updated its guidelines for assessing and responding to potential clusters of cancer cases in communities. The public comment period continues through July 15.
CAR T-cell therapy causes neurologic side effects in most patients, but the effects are temporary. (Brain, Brigham & Women's Hospital)
NPI Number cardiology consultants
By using our Services, you agree that m can use such data in accordance with our privacy policies. From a Guest Book, you may log in with your user account to leave a message. Officials with ties to current members of the administration said. "And it's all clouded because of this problem he has with Russia.". Officials who said Trump's disclosures jeopardized a critical source of intelligence on the Islamist terrorist group. Treatment for...